Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.1%

2 terminated out of 18 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed with results

Key Signals

80% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (4)
P 1 (3)
P 4 (1)

Trial Status

Completed8
Recruiting4
Unknown3
Terminated2
Not Yet Recruiting1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT04759001Phase 1Recruiting

FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae

NCT06036628Completed

Resistant Bacteria in Children in France

NCT04335383Recruiting

Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies

NCT05791396Phase 1Recruiting

FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae

NCT06148480Recruiting

Perinatal Transmission of MDR Bacteria

NCT05048693CompletedPrimary

Use of New Antibiotics in Sweden

NCT06370299Not Yet RecruitingPrimary

Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the Patient

NCT05897801Completed

Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO

NCT06199141Completed

Multi-drug Resistant Gram-negative Bacteria and Veno-venous Extracorporeal Membrane Oxygenation (ECMO)

NCT05549427Completed

Ventilator Associated Pneumonia by Multi-Drug Resistant Organism

NCT05100407CompletedPrimary

Factors Impacting the Prevalence of MDR Bacteria

NCT04181112Not ApplicableUnknownPrimary

Fecal Transplant for MDRO Decolonization

NCT04995133Phase 4Unknown

Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.

NCT04212130Not ApplicableCompleted

Can Environmental Cleanliness be Assessed by BCA (Bicinchoninic Acid) Method

NCT02906774TerminatedPrimary

Fecal Transplant for MDR Pathogen Decolonization

NCT03921645Not ApplicableUnknown

Use of Aaerosol Combined With Intravenous Antibiotics for the Treatment of Multidrug Resistant GNB Pneumonia

NCT02909946Not ApplicableCompletedPrimary

Pathway From Functional Disability to Antimicrobial Resistance in Nursing Home Residents

NCT03309358Phase 1Terminated

A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis

Showing all 18 trials

Research Network

Activity Timeline